BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, May 9, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 20, 2011
View Archived Issues
Small-molecule inhibitors of ezrin developed to target bone cancer
Read More
U.S. study uncovers candidate SNPs associated with susceptibility to cold sores
Read More
Vertex Pharmaceuticals synthesizes novel products
Read More
Isis Pharmaceuticals expands pipeline
Read More
DSMB recommends continuation of VISTA-16 trial
Read More
Vernalis and Lundbeck collaboration reaches second milestone
Read More
Neovacs completes recruitment in phase II TNF-Kinoid trial
Read More
New inhibitor of cyclin-dependent kinase 9 shows preclinical potential in CLL
Read More
Chugai Pharmaceutical presents new MEK 1 inhibitor
Read More
Novel biomarker for B-cell lymphoma discovered in Japan
Read More
New prodrugs of a coagulation factor VIIa inhibitor designed by Eisai
Read More
Novel GPR52 receptor agonists disclosed by Takeda Pharmaceutical
Read More
U.K. team presents novel cyclophilin inhibitors
Read More
New chelating cyclopeptides prepared by French group
Read More
Impax advances IPX-159 to phase IIb testing
Read More
FDA clears assay to help predict prognosis of patients with heart failure
Read More
Millennium Pharmaceuticals patents new histone deacetylase 6 inhibitors
Read More
Sanofi sells Dermik
Read More
Rib-X Pharmaceuticals reports data from phase IIb delafloxacin study
Read More
NeurogesX gives update on Qutenza sNDA
Read More
Gilead Sciences submits sNDA for Truvada
Read More
StemCells completes treatment of first cohort in phase I/II spinal cord injury trial
Read More
Dicerna and Kyowa Hakko Kirin select DsiRNA candidate for development
Read More
ThromboGenics and BioInvent complete enrollment in phase IIb TB-402 study
Read More
FDA does not require REMS program for Korlym in Cushing's syndrome
Read More
Vertex gives update on Kalydeco NDA and MAA
Read More
